Right on the heels of our press release announcing a deal with Novo Nordisk, we're thrilled to see this NY Times coverage of the partnership and Variant Bio's ethics-first approach to drug discovery: https://t.co/ehNLqmvPch
Join our webinar with Dr. Olivia Gray (@VariantBio) tomorrow!
Learn how multiomics revealed mechanisms affecting creatinine-based eGFR estimates in African ancestry populations.
📅 27 May
🕒 11 am EDT | 5 pm CEST
🔗https://t.co/mQVsUg0tOS
Can genetics bias kidney disease biomarkers?
In our next webinar, Dr. Olivia Gray (@VariantBio) will show how multiomics revealed mechanisms affecting creatinine-based eGFR estimates in African ancestry populations.
📅 27 May
🕑 11 am EDT | 5 pm CEST
🔗 https://t.co/mQVsUg0tOS
In honor of International Nurses Day -- celebrated on the anniversary of Florence Nightingale's birth -- the team @VariantBio owes a huge THANK YOU to nurses around the world (including in Tahiti, pictured here) who make our research studies possible. Cheers to nurses everywhere!
Dr. Moira Gunn from @biotechnation interviewed @AndrewFarnum and Dr. Sarah LeBaron von Baeyer from @VariantBio for NPR this week on how AI, ethics, and diverse data can help us develop better drugs and diagnostics: https://t.co/nEzBug4Wqo
Alpha in biotech comes from looking where no one else is. At @VariantBio, we’ve built a proprietary engine to uncover human genetic evidence that the rest of the industry is missing. I had a great deep dive into the ethics and science of our approach on @biotechnation today.
“In the era of precision medicine, [a]dding more data from the global north may offer only incremental insight, whereas African data has the potential for genuinely novel discovery. It is a meaningful step toward inclusion and equity”: https://t.co/Pp1glZE0hI
In honor of National Doctors' Day today, we would like to thank all the doctors we have worked with in partner communities around the world, as well as the doctors who are committed to helping patients with the new medicines we are developing @VariantBio.
Coverage of Variant Bio's collaboration with Prof. Lyn Griffiths and the QUT Centre for Genomics and Personalised Health on the genetic and multi-omic landscape of metabolic conditions in Pasifika communities in Australia: https://t.co/E3UQOpnTgf
Variant Bio recently launched a study with Novo Nordisk, this time in partnership with the University of Otago and Pukapuka Community Group: https://t.co/r1O7goSEeL
We published an open-access article on how to apply flexible benefit-sharing models to genomic research projects in South Africa and beyond: https://t.co/CYksKF3OfS
An anthropologist and a geneticist from Variant Bio teamed up with partners in New Caledonia to return study results one island at a time: https://t.co/5Vph1maqkY
Coinciding with our most recent pharma collaboration, we officially launched our Inference agentic AI platform and an accompanying website: https://t.co/tPlo1RN8CY
1/ Big news today from Lux family co Variant Bio 🧬📈@VariantBio
Announced its new Inference platform is now available to research partners + has collaborations with several pharmaceutical companies in deals totaling more than $200 million including Boehringer + Novo Nordisk...
Harnessing genomics and AI agents in drug discovery, platform underpins new kidney disease collaboration with Boehringer Ingelheim.
https://t.co/q1uYhqC2uD
#longevity#biotech#drugdiscovery#AI#pharma